{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:34:53Z","timestamp":1791304493882,"version":"4.3.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system, distinct from multiple sclerosis, characterized by severe inflammatory attacks targeting the optic nerves, spinal cord, and brainstem. Treatment has evolved from broad immunosuppressants to targeted biologics, such as complement inhibitors (ravulizumab\/eculizumab), supported by strong evidence, including the CHAMPION-NMOSD trial for ravulizumab in AQP4-Ab+ve NMOSD patients. This case highlights the importance of prompt diagnosis and innovative treatment approaches in the management of NMOSD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 20-year-old woman presented with acute brainstem dysfunction (dysarthria, diplopia) and a 1-month history of area postrema syndrome (APS), progressing to dysphagia and dyspnea requiring ICU admission. Diagnostic workup revealed AQP4-IgG+ NMOSD with characteristic lesions in the area postrema, pons, and cervical cord (C1\u2013C3). The patient achieved complete clinical recovery with ravulizumab, with near-complete radiological resolution at 3 months and clinical and radiological stability through ~24 months of follow-up, highlighting the efficacy of post-acute initiation of complement inhibition in severe NMOSD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case demonstrates the diagnostic and therapeutic challenges of AQP4-IgG+ NMOSD in a young patient presenting with area postrema syndrome. The patient remained clinically stable and free of new MRI activity through ~24 months of follow-up on ravulizumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1827687","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:45:27Z","timestamp":1781239527000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ravulizumab for relapse prevention in AQP4-IgG\u2013positive neuromyelitis optica spectrum disorder: a 2-year follow-up case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Nabil","family":"Akkawi","sequence":"first","affiliation":[{"name":"Neurology, HMS Mirdif Hospital","place":["Dubai, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elkhansa Hassabo","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Neurology, HMS Mirdif Hospital","place":["Dubai, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Shatila","sequence":"additional","affiliation":[{"name":"Neurology, Sheikh Shakhbout Medical City","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2013 revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.26444\/jpccr\/208392","article-title":"Exploring treatment approaches for Neuromyelitis Optica Spectrum Disorders (NMOSD)","volume":"19","author":"Kozi\u0144ska","year":"2025","journal-title":"J Pre-Clinical Clin Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40259-020-00460-9","article-title":"Emerging targeted therapies for neuromyelitis optica spectrum disorders","volume":"35","author":"Valencia-Sanchez","year":"2021","journal-title":"BioDrugs."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in Aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e82650","DOI":"10.7759\/cureus.82650","article-title":"Aggressive and refractory attack of AQP4-IgG-positive neuromyelitis optica spectrum disorder treated with ravulizumab: a case report","volume":"17","author":"Vald\u00e9s","year":"2025","journal-title":"Cureus."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e75827","DOI":"10.7759\/cureus.75827","article-title":"A case of neuromyelitis optica spectrum disorder with improvement in urinary retention after the administration of ravulizumab","volume":"16","author":"Saito","year":"2024","journal-title":"Cureus."},{"key":"B10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/cen3.12458","article-title":"Prevalence and characteristics of transverse myelitis and neuromyelitis optica spectrum disorders in the United Arab Emirates: a multicenter, retrospective study","volume":"9","author":"Holroyd","year":"2018","journal-title":"Clin Exp Neuroimmunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/13524585241292797","article-title":"How to avoid missing a diagnosis of neuromyelitis optica spectrum disorder","volume":"31","author":"Carnero Contentti","year":"2025","journal-title":"Mult Scler J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain."},{"key":"B13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.25259\/JNRP_83_2022","article-title":"Area postrema syndrome: an unusual presentation of neuromyelitis optica spectrum disorder","volume":"14","author":"Raj","year":"2023","journal-title":"J Neurosci Rural Pract."},{"key":"B14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40263-025-01260-x","article-title":"Consensus recommendations for the diagnosis and treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): the MENACTRIMS guidelines","volume":"40","author":"Yamout","year":"2026","journal-title":"CNS Drugs."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1332890","DOI":"10.3389\/fneur.2024.1332890","article-title":"Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder","volume":"15","author":"Ortiz","year":"2024","journal-title":"Front Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"E1642","DOI":"10.1212\/WNL.0000000000006392","article-title":"Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG-positive NMOSD","volume":"91","author":"Shosha","year":"2018","journal-title":"Neurology."},{"key":"B19","article-title":"Long-term efficacy and safety of ravulizumab in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: Final analysis of the phase 3 CHAMPION-NMOSD trial [Oral Presentation]","volume-title":"European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting","author":"Pittock","year":"2025"},{"key":"B20","doi-asserted-by":"publisher","first-page":"106747","DOI":"10.1016\/j.msard.2025.106747","article-title":"Post marketing real-world experience of ravulizumab in NMOSD","volume":"104","author":"Jacob","year":"2025","journal-title":"Mult Scler Relat Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1671145","DOI":"10.3389\/fimmu.2025.1671145","article-title":"Ravulizumab in NMOSD with associated interstitial pneumonitis in a 59-year-old female patient: a case report","volume":"16","author":"Neundorf","year":"2026","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/brb3.70472","article-title":"Impact of Treatment delay and prognostic factors in acute myelitis of neuromyelitis optica spectrum disease","volume":"15","author":"Zhou","year":"2025","journal-title":"Brain Behav."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e84703","DOI":"10.7759\/cureus.84703","article-title":"Ravulizumab is effective and safe for neuromyelitis optica spectrum disorder patients in various clinical settings: a single-center case series with concomitant use of rituximab","volume":"17","author":"Amano","year":"2025","journal-title":"Cureus."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e70472","DOI":"10.1136\/bmjno-2025-001286","article-title":"Transplacental transfer of ravulizumab in a pregnant woman with neuromyelitis optica: a case report","volume":"7","author":"Jacob","year":"2025","journal-title":"BMJ Neurol Open."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1827687\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:45:40Z","timestamp":1781239540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1827687\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":24,"alternative-id":["10.3389\/fmed.2026.1827687"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1827687","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"1827687"}}